Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Asthma is a heterogeneous disease that can be classified into different clinical endotypes, depending on the type of airway inflammation, clinical severity, and response to treatment. This article focuses on the eosinophilic endotype of asthma, which is defined by the central role that eosinophils play in the pathophysiology of the condition. It is characterized by persistently elevated sputum and/or blood eosinophils and by a significant response to treatments that suppress eosinophilia. Eosinophil activity in the airway may be more important than their numbers and this needs to be investigated. Transcriplomic or Metabolomic signatures may also be useful to identify this endotype.

Original publication

DOI

10.1016/j.iac.2016.04.001

Type

Journal article

Journal

Immunol Allergy Clin North Am

Volume

36

Pages

609 - 623

Keywords

Anti-IL-13, Anti-IL-4&13, Anti-IL-5, Biomarkers, Severe asthma, Type-2 cytokines, Anti-Asthmatic Agents, Asthma, Biological Products, Biomarkers, Clinical Trials as Topic, Cytokines, Eosinophilia, Humans, Phenotype, Severity of Illness Index, Th2 Cells, Treatment Outcome